ConductScience.org, home

Paper17526015

Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats.

Gary-Bobo M and 19 others. Hepatology, 2007. Cited by 247 papers, by iCite.

Cite this record

ConductScience Library. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Papers, record 17526015. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17526015

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats.
PubMed
Journal
Hepatology
PubMed
Year
2007
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
247
iCite
Relative citation ratio, by iCite
6.37
iCite
Revised in PubMed
2022-02-24
PubMed

Authors20

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Gary-Bobo MMagali
2Elachouri GGhizlane
3Gallas JFJean François
4Janiak PPhilip
5Marini PPietro
6Ravinet-Trillou CChristine
7Chabbert MMichèle
8Cruccioli NNoël
9Pfersdorff CChristian
10Roque CClaude
11Arnone MMichèle
12Croci TTiziano
13Soubrié PPhilippe
14Oury-Donat FFlorence
15Maffrand JPJean Pierre
16Scatton BBernard
17Lacheretz FFrederic
18Le Fur GGérard
19Herbert JMJean Marc
20Bensaid MMohammed

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Fatty LiverMajor topic
Metabolic SyndromeMajor topic
ObesityMajor topic
PiperidinesMajor topic
PyrazolesMajor topic
Animals
Cannabinoid Receptor Antagonists
Inflammation
Liver
Male
RNA
Rats
Rats, Zucker
Reverse Transcriptase Polymerase Chain Reaction
Rimonabant
Tumor Necrosis Factor-alpha

Source PubMed

Download CSV of topics

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in17596867Food energy efficiency, cannabinoids, and a slow death of the weight loss dogma.https://conductscience.org/library/papers/17596867

Source PubMed

Download CSV of comments and corrections

Cited by120

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 247 citations.

PMIDTitleJournalYearIn PapersSource
41869774Acute metabolic effects of cannabinoid receptor modulators during sequential hyperglycemic, euglycemic-hyperinsulinemic clamps in healthy individuals.Am J Physiol Endocrinol Metab2026https://conductscience.org/library/papers/41869774PubMed
41867680Taurine attenuates lipid accumulation via the eCB-CB1 axis: evidence from adipose metabolomics in HFD-fed mice and 3D adipocyte spheroids.Front Nutr2026https://conductscience.org/library/papers/41867680PubMed
40290527Cannabinoids and the endocannabinoid system in liver diseases.Clin Exp Hepatol2024https://conductscience.org/library/papers/40290527PubMed
39941074The Endocannabinoid System: Implications in Gastrointestinal Physiology and Pathology.Int J Mol Sci2025https://conductscience.org/library/papers/39941074PubMed
39296275Novel Peripherally Selective Cannabinoid Receptor 1 Neutral Antagonist Improves Metabolic Dysfunction-Associated Steatotic Liver Disease in Mice.ACS Pharmacol Transl Sci2024https://conductscience.org/library/papers/39296275PubMed
39292202The endocannabinoid system in appetite regulation and treatment of obesity.Pharmacol Res Perspect2024https://conductscience.org/library/papers/39292202PubMed
37371762Exploring the Therapeutic Potential of Cannabinoid Receptor Antagonists in Inflammation, Diabetes Mellitus, and Obesity.Biomedicines2023https://conductscience.org/library/papers/37371762PubMed
36442615Hepatic targeting of the centrally active cannabinoid 1 receptor (CB1R) blocker rimonabant via PLGA nanoparticles for treating fatty liver disease and diabetes.J Control Release2023https://conductscience.org/library/papers/36442615PubMed
36329422Circulating endocannabinoid levels in pregnant women with gestational diabetes mellitus: a case-control study.BMC Endocr Disord2022https://conductscience.org/library/papers/36329422PubMed
35420457Expanding Research on Cannabis-Based Medicines for Liver Steatosis: A Low-Risk High-Reward Way Out of the Present Deadlock?Cannabis Cannabinoid Res2023https://conductscience.org/library/papers/35420457PubMed
35328343Chemical Synthesis, Pharmacokinetic Properties and Biological Effects of JM-00266, a Putative Non-Brain Penetrant Cannabinoid Receptor 1 Inverse Agonist.Int J Mol Sci2022https://conductscience.org/library/papers/35328343PubMed
34754376Metabolic and inflammatory functions of cannabinoid receptor type 1 are differentially modulated by adiponectin.World J Diabetes2021https://conductscience.org/library/papers/34754376PubMed
34610720Rho-Kinase as a Therapeutic Target for Nonalcoholic Fatty Liver Diseases.Diabetes Metab J2021https://conductscience.org/library/papers/34610720PubMed
34220518Suppression of Inflammatory Cardiac Cytokine Network in Rats with Untreated Obesity and Pre-Diabetes by AT2 Receptor Agonist NP-6A4.Front Pharmacol2021https://conductscience.org/library/papers/34220518PubMed
33896380At the heart of microbial conversations: endocannabinoids and the microbiome in cardiometabolic risk.Gut Microbes2021https://conductscience.org/library/papers/33896380PubMed
33562080Interference with TGFβ1-Mediated Inflammation and Fibrosis Underlies Reno-Protective Effects of the CB1 Receptor Neutral Antagonists AM6545 and AM4113 in a Rat Model of Metabolic Syndrome.Molecules2021https://conductscience.org/library/papers/33562080PubMed
33138155Effects of the CB1 Receptor Antagonists AM6545 and AM4113 on Insulin Resistance in a High-Fructose High-Salt Rat Model of Metabolic Syndrome.Medicina (Kaunas)2020https://conductscience.org/library/papers/33138155PubMed
32987186Reversal of diet-induced hepatic steatosis by peripheral CB1 receptor blockade in mice is p53/miRNA-22/SIRT1/PPARα dependent.Mol Metab2020https://conductscience.org/library/papers/32987186PubMed
32927872A Peripheral CB1R Antagonist Increases Lipolysis, Oxygen Consumption Rate, and Markers of Beiging in 3T3-L1 Adipocytes Similar to RIM, Suggesting that Central Effects Can Be Avoided.Int J Mol Sci2020https://conductscience.org/library/papers/32927872PubMed
32798334Cannabinoid receptor type 1 antagonist inhibits progression of obesity-associated nonalcoholic steatohepatitis in a mouse model by remodulating immune system disturbances.Immun Inflamm Dis2020https://conductscience.org/library/papers/32798334PubMed

See all 120 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17526015

GET https://conductscience.org/api/papers/v1/17526015/cited_by?page=2